A double-blind, multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of adjunctive treatment with 3000 mg/day (pediatric target dose of 60 mg/kg/day) oral levetiracetam (LEV) (166, 250, and 500mg Tablets), in adult and pediatric subjects (4-65 Years) suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures.

Trial Profile

A double-blind, multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of adjunctive treatment with 3000 mg/day (pediatric target dose of 60 mg/kg/day) oral levetiracetam (LEV) (166, 250, and 500mg Tablets), in adult and pediatric subjects (4-65 Years) suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Levetiracetam (Primary)
  • Indications Epilepsy; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Sponsors UCB; UCB Pharma Inc
  • Most Recent Events

    • 20 Oct 2009 UCB added as trial sponsor as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Secondary analysis results published in Epilepsy Research.
    • 03 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top